Inversago Pharma 
Welcome,         Profile    Billing    Logout  
 4 Products   0 Diseases  4 Products   2 Trials   47 News 
6 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
zevaquenabant (INV-101) / Novo Nordisk
NCT05844592: First in Human, Single Ascending Dose Study

Completed
1
40
RoW
INV-101
Innovo Therapeutics, Inc.
Ulcerative Colitis
07/22
08/22
NCT06938204: Single Ascending Dose, Multiple Ascending Dose, Food Effect Study

Completed
1
48
US
INV-101, INV-101 Placebo
Innovo Therapeutics, Inc.
Healthy Volunteer
08/24
09/24
monlunabant (NN9440) / Novo Nordisk
2022-002140-51: Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease 2. fázisú vizsgálata diabéteszes vesebetegségben szenvedő betegeken

Not yet recruiting
2
240
Europe
INV-202, INV-202, Tablet
Inversago Pharma Inc., Inversago Pharma Inc.
Diabetic Kidney Disease diabéteszes vesebetegségben szenvedő, Diabetic Kidney Disease diabéteszes vesebetegségben szenvedő, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT05514548 / 2022-002140-51: Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

Completed
2
265
Europe, Canada, US, RoW
INV-202, None applicable, Placebo
Inversago Pharma Inc., Worldwide Clinical Trials
Diabetic Kidney Disease
08/24
09/24
NCT05891834: Study of INV-202 in Patients With Obesity and Metabolic Syndrome

Completed
2
243
Canada
INV-202, Placebo
Inversago Pharma Inc.
Obesity, Metabolic Syndrome
06/24
02/25
NCT06542536: A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men

Completed
1
73
US
Monlunabant, Placebo (monlunabant)
Novo Nordisk A/S
Obesity
10/24
10/24
INV-201 / Novo Nordisk
No trials found
INV-300 SERIES / Novo Nordisk
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
zevaquenabant (INV-101) / Novo Nordisk
NCT05844592: First in Human, Single Ascending Dose Study

Completed
1
40
RoW
INV-101
Innovo Therapeutics, Inc.
Ulcerative Colitis
07/22
08/22
NCT06938204: Single Ascending Dose, Multiple Ascending Dose, Food Effect Study

Completed
1
48
US
INV-101, INV-101 Placebo
Innovo Therapeutics, Inc.
Healthy Volunteer
08/24
09/24
monlunabant (NN9440) / Novo Nordisk
2022-002140-51: Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease 2. fázisú vizsgálata diabéteszes vesebetegségben szenvedő betegeken

Not yet recruiting
2
240
Europe
INV-202, INV-202, Tablet
Inversago Pharma Inc., Inversago Pharma Inc.
Diabetic Kidney Disease diabéteszes vesebetegségben szenvedő, Diabetic Kidney Disease diabéteszes vesebetegségben szenvedő, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT05514548 / 2022-002140-51: Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

Completed
2
265
Europe, Canada, US, RoW
INV-202, None applicable, Placebo
Inversago Pharma Inc., Worldwide Clinical Trials
Diabetic Kidney Disease
08/24
09/24
NCT05891834: Study of INV-202 in Patients With Obesity and Metabolic Syndrome

Completed
2
243
Canada
INV-202, Placebo
Inversago Pharma Inc.
Obesity, Metabolic Syndrome
06/24
02/25
NCT06542536: A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men

Completed
1
73
US
Monlunabant, Placebo (monlunabant)
Novo Nordisk A/S
Obesity
10/24
10/24
INV-201 / Novo Nordisk
No trials found
INV-300 SERIES / Novo Nordisk
No trials found

Download Options